Sermorelin Acetate + NAD+: A Longevity Strategy for Menopause, Andropause, and Metabolic Health
About the Author
Dr. Corina Ianculovici, DNP, FAAMFM, ABAAM-HP, is a board-certified advanced practice clinician specializing in
longevity medicine, metabolic health, and hormone optimization and functional aesthetics.
She is the founder of Mirelle Institute for Anti-Aging Medicine in New Jersey.
How Peptide Therapy, Cellular Energy Support, and Hormone Optimization Work Together to Support Healthy Aging
At Mirelle Institute for Anti-Aging Medicine, one of the most promising clinical strategies for supporting metabolic and hormonal health involves a carefully designed Sermorelin Acetate and NAD+ therapy stack.
When used as part of a clinician-guided program, these therapies may help support:
- healthy body composition
- preservation of lean muscle mass
- metabolic resilience
- cellular energy production
- recovery and vitality
Together, these therapies target several of the biological drivers of aging.
Peptides are short chains of amino acids that act as biological messengers within the body. They help regulate many essential physiological processes, including hormone release, tissue repair, and metabolism.
As we age, the efficiency of many signaling pathways declines. Longevity medicine seeks to restore these signaling networks using targeted therapies. Some peptides work by stimulating the body's natural hormone production pathways rather than replacing hormones directly.
One of the most widely used peptides in this category is Sermorelin Acetate.
What Is Sermorelin Acetate?
Growth hormone signaling naturally declines with age. This decline is associated with:
- increased body fat
- reduced lean muscle mass
- decreased physical performance
- mitochondrial energy production
- DNA repair
- oxidative stress response
- metabolic regulation
- sirtuin signaling pathways
Levels of NAD+ decline significantly with age, which may impair mitochondrial function and cellular resilience.
These two therapies work through complementary biological mechanisms.
- Sermorelin supports hormonal signaling through the GH/IGF-1 pathway.
- NAD+ supports mitochondrial energy production and cellular repair mechanisms.
Together, they target two central aspects of aging biology:
- Declining endocrine signaling
- Declining cellular energy production
When combined with proper nutrition, strength training, and sleep optimization, this approach may help support:
- metabolic resilience
- recovery and vitality
- healthy body composition
- improved cellular function
- insulin resistance
- cardiovascular disease
- metabolic syndrome
- systemic inflammation
At the same time, aging is associated with sarcopenia, the progressive loss of muscle mass and strength. Muscle tissue is essential for metabolic health, glucose regulation, and long-term physical independence (Cruz-Jentoft et al., Age and Ageing).
Preserving lean mass while improving metabolic efficiency is therefore a major focus of modern anti-aging medicine.
Poor sleep is also associated with:
- increased obesity risk
- insulin resistance
- cardiovascular disease
- impaired cognitive performance
Improving sleep quality is therefore one of the most powerful interventions for metabolic health (Tasali et al., Nature Reviews Endocrinology).
Supporting Men Through Andropause
- fatigue
- reduced libido
- increased abdominal fat
- loss of muscle mass
- decreased energy and motivation
For men with clinically confirmed testosterone deficiency, testosterone replacement therapy may be appropriate under physician supervision (Endocrine Society Clinical Practice Guidelines).
Peptide therapies such as Sermorelin may serve as adjunctive tools within a broader metabolic and hormonal optimization strategy.
Menopause is a major hormonal transition characterized by declining estrogen and progesterone levels. Symptoms can include:
- hot flashes
- weight gain
- sleep disturbances
- fatigue
- changes in body composition
Hormone therapy remains the most effective treatment for vasomotor symptoms and menopause-related sleep disruption, according to the Menopause Society position statement (2022).
GLP-1-based medications improve metabolic health by:
- reducing appetite
- improving insulin sensitivity
- promoting fat loss
Large clinical trials such as the SURPASS trial have demonstrated significant reductions in body weight and visceral adipose tissue with GLP-1/GIP therapies like tirzepatide (Frías et al., New England Journal of Medicine). However, substantial weight loss can also lead to loss of lean muscle mass.
- Sermorelin peptide therapy
- NAD+ cellular support therapy
- Bioidentical hormone replacement therapy (BHRT)
- GLP-1/GIP metabolic optimization
- body composition analysis and muscle preservation strategies
- sleep and recovery optimization
Patients can also explore treatment possibilities using our advanced AI tools:
Conclusion






